CN104619334A - 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 - Google Patents

超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 Download PDF

Info

Publication number
CN104619334A
CN104619334A CN201380047839.4A CN201380047839A CN104619334A CN 104619334 A CN104619334 A CN 104619334A CN 201380047839 A CN201380047839 A CN 201380047839A CN 104619334 A CN104619334 A CN 104619334A
Authority
CN
China
Prior art keywords
receptor
cytokine
mutein
cells
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047839.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·K·加西亚
D·L·巴特斯
I·莫拉加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN201910717548.0A priority Critical patent/CN110615835A/zh
Publication of CN104619334A publication Critical patent/CN104619334A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380047839.4A 2012-08-09 2013-08-08 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 Pending CN104619334A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910717548.0A CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US61/681490 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US61/725791 2012-11-13
US201361825980P 2013-05-21 2013-05-21
US61/825980 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910717548.0A Division CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Publications (1)

Publication Number Publication Date
CN104619334A true CN104619334A (zh) 2015-05-13

Family

ID=50685291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380047839.4A Pending CN104619334A (zh) 2012-08-09 2013-08-08 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
CN201910717548.0A Pending CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910717548.0A Pending CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Country Status (6)

Country Link
US (3) US9738696B2 (https=)
EP (1) EP2882449B1 (https=)
JP (2) JP6445434B2 (https=)
CN (2) CN104619334A (https=)
IN (1) IN2015KN00329A (https=)
WO (1) WO2014074186A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582293A (zh) * 2017-03-31 2019-12-17 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2020212598A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
EP4532018A4 (en) * 2022-05-24 2026-04-22 Univ Pittsburgh Commonwealth Sys Higher Education EYE COMPOUNDS BASED ON INTERLEUKIN 4 AND/OR INTERLEUKIN 13

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
AU2001288405B8 (en) 1998-04-03 2007-06-14 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
AU780163B2 (en) 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
WO2001025282A1 (en) 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants
EP1263785A2 (en) 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
WO2002101629A1 (en) 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
CA2593648A1 (en) 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
JP5114418B2 (ja) 2005-09-09 2013-01-09 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ 細胞死を抑制する又は細胞増殖を高めるための方法及び組成物
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2008101671A2 (en) 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2197909A4 (en) 2007-08-24 2014-12-03 Univ Minnesota REAGENTS ON RECIPES
CN102112144A (zh) 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
TWI397428B (zh) 2009-12-29 2013-06-01 財團法人工業技術研究院 標的第四介白素受體之傳輸系統
WO2011106779A1 (en) 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
JP5734951B2 (ja) 2010-03-03 2015-06-17 シャープ株式会社 表示装置およびその駆動方法、ならびに液晶表示装置
AU2011316786A1 (en) 2010-10-22 2013-05-02 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
WO2012139112A1 (en) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
WO2015070210A1 (en) 2013-11-11 2015-05-14 Wake Forest University Health Sciences Epha3 and multi-valent targeting of tumors
BR112016018100A2 (pt) 2014-02-07 2018-02-20 Univ Mcmaster acoplador antigênico de células t trifuncional, métodos e usos do mesmo
CA2972714A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
JP2017537622A (ja) 2014-12-02 2017-12-21 ロジャー・ウィリアムズ・ホスピタル がんを治療するための方法及び組成物
WO2017122130A1 (en) 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
CN113728232A (zh) 2019-02-07 2021-11-30 梅迪塞纳医疗股份有限公司 作为癌症中的生物标志物的il-4r
CN116390744A (zh) 2020-06-24 2023-07-04 梅迪塞纳医疗股份有限公司 双功能性超级因子及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATES D. L. ET AL.: "3QB7：Interleukin-4 mutant RGA bound to cytokine receptor common gamma", 《RCSB PDB》 *
CREUSOT ET AL.: "Engineering cell-type selective immune responses using mechanism-based designer IL-4 cytokines", 《THE JOURNAL OF IMMUNOLOGY》, vol. 186, 31 December 2011 (2011-12-31) *
SCHNARE ET AL.: "Specific Antagonism of Type I IL-4 Receptor with a Mutated Form of Murine IL-4", 《THE JOURNAL OF IMMUNOLOGY》, vol. 161, 31 December 1998 (1998-12-31) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582293A (zh) * 2017-03-31 2019-12-17 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines

Also Published As

Publication number Publication date
US9738696B2 (en) 2017-08-22
EP2882449A4 (en) 2016-03-09
JP6445434B2 (ja) 2018-12-26
JP2015525574A (ja) 2015-09-07
WO2014074186A2 (en) 2014-05-15
US10738096B2 (en) 2020-08-11
EP2882449B1 (en) 2019-05-15
JP2018161143A (ja) 2018-10-18
IN2015KN00329A (https=) 2015-07-10
US20160244499A1 (en) 2016-08-25
US20180016316A1 (en) 2018-01-18
US20210188932A1 (en) 2021-06-24
WO2014074186A3 (en) 2014-06-19
CN110615835A (zh) 2019-12-27
US12187771B2 (en) 2025-01-07
EP2882449A2 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
US12187771B2 (en) Method of producing Th9 T-cells
JP7729570B2 (ja) インターロイキン－２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
Bernstein et al. Engineering the IL‐4/IL‐13 axis for targeted immune modulation
JP6441867B2 (ja) インターロイキン２のスーパーアゴニストおよびアンタゴニスト
CN110392695B (zh) 针对cd127的抗体和多肽
AU2005277236A1 (en) Methods and compositions for treating allergic inflammation
US20110311475A1 (en) Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
CN112843222A (zh) Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN114380919A (zh) 经修饰的il-2分子及其用途
TW202330631A (zh) ＳＩＲＰａ突變體及其應用
CN103382220A (zh) 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
WO2022036196A2 (en) Use of vista agonist for treatment/prevention of cytokine storm or crs or sepsis and/or acute or chronic respiratory distress syndrome (rds)
CA2946398C (en) Superagonists, partial agonists and antagonists of interleukin-2
Rosenberg et al. Characterization of Lamprey IL-17 Family

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150513

RJ01 Rejection of invention patent application after publication